Phase III Randomized Controlled Trial Layout with Bento-Grid Architecture
Design: Multicenter, randomized, double-blind, placebo-controlled event-driven superiority trial.
Primary Hypothesis: Experimental agent reduces primary composite endpoint vs. standard of care placebo.
Statistical Power: 90% power to detect a 20% relative risk reduction with two-sided α = 0.05.
Summary of Primary, Secondary, and Adverse Safety Endpoints formatted with statistical rigor.
Multi-part question stem evaluating statistical interpretation, intention-to-treat methodology, and clinical application.